Research programme: pain therapy - EQiTXAlternative Names: ZingoTX
Latest Information Update: 13 Jul 2011
At a glance
- Originator EQiTX
- Mechanism of Action TRPV1 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 03 Aug 2005 Preclinical trials in Pain in Australia (unspecified route)
- 03 Aug 2005 This programme is available for licensing (http://www.eqitx.com)